HIV Market Research Reports

HIV (human immunodeficiency virus) had ravaging impact over the last two decades touching millions of people economic, social, health and psychological conditions. More people are prone to HIV infection due to lack of awareness about the virus and changes in lifestyle. Inspite of the more efforts made by government authorities and several philanthropic institutions, the numbers of HIV infection are higher across the world.

The HIV treatment is more effective with the treatment of Highly Active Antiretroviral Therapy (HAART), helps to lower down the HIV particles in the blood cell, hence decreasing the complications in AIDS related mortality. The HIV market reigns by Atripla products such as NRTIs, NNRTIs, PIs, Fusion Inhibitors, zidovudine, didanosine, stavudine and lamivudine and Combivir (lamivudine/Zidovudine). The global HIV market also demands novel HIV drugs medication due to the expiration of main antiviral drugs patent in the coming years, major issues such as resistance ...
View More

HIV (human immunodeficiency virus) had ravaging impact over the last two decades touching millions of people economic, social, health and psychological conditions. More people are prone to HIV infection due to lack of awareness about the virus and changes in lifestyle. Inspite of the more efforts made by government authorities and several philanthropic institutions, the numbers of HIV infection are higher across the world.

The HIV treatment is more effective with the treatment of Highly Active Antiretroviral Therapy (HAART), helps to lower down the HIV particles in the blood cell, hence decreasing the complications in AIDS related mortality. The HIV market reigns by Atripla products such as NRTIs, NNRTIs, PIs, Fusion Inhibitors, zidovudine, didanosine, stavudine and lamivudine and Combivir (lamivudine/Zidovudine). The global HIV market also demands novel HIV drugs medication due to the expiration of main antiviral drugs patent in the coming years, major issues such as resistance to ART drugs and increasing more HIV infections.

The global market for HIV Testing is driven by the growing adoption of HIV testing procedures, increase in rapid HIV test kits, home HIV testing procedures and introduction of new drugs such as integrase, entry and maturation inhibitors. Generics market is expected to absorb antiviral drugs market for HIV medication showed largest market share in total generic antivirals market. The market growth considers licensing agreements and drug approvals as key factor for HIV testing procedures.

However, many key drug patents are expected to expire such as Sustiva (efavirenz) and Kaletra (lopinavir + ritonavir) in 2013, Prezista (darunavir ethanolate) in 2014, and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) such as Trizivir (abacavir sulphate/lamivudine/zidovudine), Epzicom (lamivudine and abacavir) and Emtriva (emtricitabine) in 2016. The expiry of patents will produce new drugs to address the unmet need of the market. Some of the HIV drugs which are in late stage development phase such as Cobicistat and Elvitegravir by Gilead Sciences, and GSK-1349572 by ViiV Healthcare and Shionogi mold the global HIV market.

The US and Europe reigns the global HIV market by contributing major share of the revenues for HIV/AIDS testing. Developing countries from Asia-Pacific region represents the fastest growing market for HIV/AIDS testing. The major players dominates the market includes GSK, Gilead, BMS, Abbott, Roche, Boehringer Ingelheim, Pfizer, Merck, Barr and Kohl Medical.
View Less